Table of Contents
Sleep Medicine Market Overview
Sleep medicine is dedicated to diagnosing and treating sleep issues. It is becoming increasingly vital due to growing awareness of sleep’s importance for health.
The demand for sleep analysis, wearable trackers, and treatments is rising, driven by stress, obesity, and lifestyle shifts.
Technological advancements, like wearables and telemedicine, have revolutionized this field, allowing for customized patient care.
The sector is experiencing significant growth, spurred by investments in health. Technological progress, and a better understanding of sleep’s health impacts.
As it progresses, sleep medicine is expected to blend more technology and personalized care. Underscoring sleep’s role in comprehensive health and disease prevention.
Market Drivers
The global sleep medicine market is surging, driven by several key factors: the increasing occurrence of sleep disorders due to factors. Like aging, changing lifestyles, and obesity; greater awareness of sleep’s importance; and technological innovations in wearables and telemedicine enhancing accessibility to care.
Additionally, higher healthcare investment, the holistic inclusion of sleep in wellness practices, better insurance, and policy support. Plus active research and public health efforts aimed at enhancing sleep health are all fueling this sector’s growth.
Together, these elements point to a bright future for sleep medicine. With continued advancements and expanded access to treatments on the horizon.
Market Size
The Global Sleep Apnea Devices Market is projected to grow from USD 8.7 billion in 2023 to USD 17.4 billion by 2033, expanding at a 7.2% CAGR between 2024 and 2033.
List of Major Companies
These are the top ten companies operating in the Sleep Medicine Market:
- ResMed
- Fisher-and-Paykel
- Sleep-Number
- AstraZeneca
- Merck
- Philips-Respironics
- Itamar-Medical
- DeVilbiss
- SomnoMed
- Oventus
ResMed
Company Overview
| Establishment Year | 1989 |
| Headquarter | San Diego, California, U.S. |
| Key Management | Michael Farrell (CEO) |
| Revenue (US$ Bn) | $ 3.6 Billion (2022) |
| Headcount | ~ 8,160 (2022) |
| Website | http://resmed.com/ |
Business Description
Since its inception in 1989 in San Diego, ResMed Inc. has emerged as a leader in sleep medicine. Crafting and promoting medical devices and digital solutions for conditions like sleep apnea and COPD.
Its portfolio features cutting-edge CPAP, BiPAP, and ASV devices enhanced by cloud-based monitoring capabilities.
ResMed enhances patient care through digital platforms like myAir, enabling personalized therapy tracking.
Dedicated to innovation and collaboration with healthcare experts, ResMed excels in delivering patient-focused solutions that markedly improve life for individuals with sleep disorders, reinforcing its standing in the global marketplace.
Geographical Presence
ResMed Inc., headquartered in San Diego, California, boasts a vast global footprint. Serving over 140 countries with its advanced sleep medicine solutions.
The company’s operations span continents, including North America, Europe, Asia-Pacific, and beyond, with key facilities for operations, sales, and research and development.
This extensive network enables ResMed to meet diverse patient and healthcare system needs worldwide, affirming its role as a global leader in sleep and respiratory care.
Through its commitment to accessibility and innovation, ResMed shapes global healthcare practices and standards in sleep medicine.
Recent Developments
- In March 2024, ResMed launched the AirFit F40 in the U.S., an ultra-compact, full-face mask designed for comfort similar to smaller masks, aiming to enhance compliance with sleep apnea therapy without compromising on performance.
- In February 2024, ResMed introduced the AirCurve 11 series, it’s latest bilevel devices that offer dual support through inspiratory (IPAP) and expiratory (EPAP) positive airway pressures, incorporating digital technology to simplify sleep apnea treatment for healthcare providers and enhance patient adherence to therapy.
Fisher-and-Paykel
Company Overview
| Establishment Year | 1934 |
| Headquarter | East Tāmaki, Auckland, New Zealand |
| Key Management | Lewis Gradon (Managing Director and CEO) |
| Revenue (US$ Bn) | $ 1.0 B (2023) |
| Headcount | ~ 6,564 (2023) |
| Website | http://www.fphcare.com/ |
Business Description
Fisher & Paykel Healthcare Corporation Ltd stands out in the sleep medicine landscape for its innovative respiratory and sleep apnea solutions.
With a global footprint spanning over 120 countries, the company excels in producing CPAP devices, masks, and accessories designed to tackle obstructive sleep apnea and related disorders.
Central to its success is a commitment to patient-centric innovation, particularly visible in its advanced humidification systems and the F&P Simplus™ full-face mask, which are tailored for comfort and effectiveness.
Fisher & Paykel Healthcare invests heavily in research and development to push the boundaries of sleep medicine. It is a trusted partner in healthcare and a pioneer in enhancing patient care and outcomes in sleep-related breathing disorders.
Geographical Presence
Fisher & Paykel Healthcare Corporation holds a prominent global position, strategically located in key regions to meet strong demand for advanced healthcare solutions in North America and Europe, where its products enhance patient care.
The Asia-Pacific market, including Australia, New Zealand, Japan, China, and India, is crucial for addressing evolving healthcare needs. Latin America witnesses focused expansion efforts to leverage growing healthcare infrastructure.
Despite challenges, Fisher & Paykel Healthcare actively expands into the Middle East and Africa. Based in New Zealand, it maintains a strong presence in Oceania.
It emphasizes innovation and quality worldwide through its extensive distribution network and customer-centric approach, ensuring leadership in the global healthcare sector.
Recent Developments
- In October 2023, Fisher & Paykel introduced the F&P Solo mask in New Zealand and Australia, aimed at treating obstructive sleep apnea (OSA).
- In May 2022, Fisher & Paykel introduced two anesthesia-specific products, broadening the market reach of its Optiflow nasal high-flow technology within the hospital respiratory support sector.
Sleep-Number
Company Overview
| Establishment Year | 1987 |
| Headquarter | Minneapolis, Minnesota, U.S. |
| Key Management | Shelly Ibach (CEO) |
| Revenue (US$ Bn) | $ 2.1 Billion (2022) |
| Headcount | ~ 5,115 (2022) |
| Website | http://sleepnumber.com/ |
Business Description
Founded in 1987 and based in Minneapolis, Sleep Number Corporation stands out in the sleep technology sector by creating smart beds and accessories that enhance sleep quality through personalization and biometric tracking.
Renowned for its Sleep Number beds, which offer adjustable firmness and support, the company incorporates sensors to monitor sleep patterns and vital signs, offering tailored insights via its SleepIQ technology.
This commitment to personalized sleep experiences, combined with a broad U.S. retail presence and online accessibility, positions Sleep Number as a leader in leveraging technology to address individual sleep needs, making significant contributions to the field of sleep medicine and wellness.
Geographical Presence
Sleep Number Corporation has a significant presence, primarily in the United States, with an extensive network of retail outlets in major cities and suburbs.
While its global reach is not as extensive, the company strategically targets key markets like Canada and Mexico. It selects European countries to meet the rising demand for high-quality sleep products.
Furthermore, Sleep Number leverages online platforms to expand its customer base beyond physical stores, aligning with modern shopping preferences.
This balanced strategy of domestic dominance and targeted international expansion positions the company to seize opportunities in the global sleep solutions market.
Recent Development
- In April 2023, Sleep Number Corporation unveiled its latest generation of Sleep Number® smart beds and Lifestyle Furniture, designed for optimal use together but available separately. These innovations aim to enhance sleep quality and support well-being across all life stages, helping users achieve their best sleep and fullest potential.
- In October 2022, Sleep Number introduced the Climate360 smart bed, the first and only sleep solution designed to maintain the ideal sleeping temperature for users throughout the night, addressing common temperature-related sleep issues.
AstraZeneca
Company Overview
| Establishment Year | 1999 |
| Headquarter | Cambridge, England, UK |
| Key Management | Michel Demaré (Chairman) |
| Revenue (US$ Bn) | $ 45.8 Billion (2023) |
| Headcount | ~ 89,900 (2023) |
| Website | https://astrazeneca.com/ |
Business Description
AstraZeneca, a global, science-led biopharmaceutical company, doesn’t primarily focus on sleep medicine within its core areas of expertise, which include oncology, cardiovascular, renal and metabolism, and respiratory & immunology diseases.
However, its innovative approach and commitment to addressing serious health challenges impact sleep health through treatments that improve underlying conditions affecting sleep.
For instance, AstraZeneca’s advancements in respiratory & immunology benefit patients with sleep-disordered breathing, such as obstructive sleep apnea, by managing conditions that exacerbate sleep issues.
Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries, aiming to push the boundaries of science to deliver life-changing medicines, which, by improving overall health, also contribute to better sleep outcomes for patients worldwide.
Geographical Presence
AstraZeneca, a leading biopharmaceutical company, maintains a strong global presence across North America, Europe, the Asia-Pacific region, Latin America, Africa, and the Middle East.
With operations spanning key markets such as the United States, Canada, the United Kingdom, China, and Japan, AstraZeneca strategically positions itself to address diverse healthcare needs and capitalize on emerging opportunities.
Through research collaborations, strategic partnerships, and investments in infrastructure, the company aims to deliver innovative healthcare solutions and improve patient outcomes worldwide.
Recent Development
- In March 2024, Ultomiris (ravulizumab-cwvz) received approval in the US as the first long-acting C5 complement inhibitor for treating adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- In March 2024, AstraZeneca finalized an agreement to acquire Fusion Pharmaceuticals Inc., a company focused on developing advanced radioconjugates (RCs) in clinical stages.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://msd.com/ |
Business Description
Merck & Co., Inc., globally known as MSD outside the U.S. and Canada, is a leading biopharmaceutical giant focusing on innovative research across various therapeutic areas.
Although sleep medicine isn’t Merck’s primary focus, its research in areas like oncology, neurosciences, and infectious diseases indirectly contributes to sleep health through medications that impact sleep-related conditions.
With its headquarters in Kenilworth, New Jersey, Merck’s global operations aim to improve and extend lives by delivering advanced health solutions.
Through its extensive research and global presence, Merck indirectly influences sleep medicine by addressing conditions with sleep implications, showcasing its commitment to advancing healthcare.
Geographical Presence
Merck, a major player in pharmaceuticals and life sciences, has a strong global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
Its headquarters in Kenilworth, New Jersey, serves as a central hub for research, manufacturing, and commercial activities in North America.
At the same time, key European markets like Germany and France also host significant operations. In Asia-Pacific, Merck strategically taps into growing healthcare markets in China, Japan, India, and Australia.
Furthermore, it extends its reach into Latin America and the Middle East/Africa through partnerships and subsidiaries. This extensive global footprint reflects Merck’s dedication to serving diverse populations and advancing healthcare solutions worldwide.
Recent Developments
- In March 2024, Merck expanded its Shanghai M Lab™ Collaboration Center, the largest in its network of ten global labs, with a €14 million investment. This expansion includes a new biology application lab, a process development training center, and an upstream application lab, enhancing the facility’s capabilities in Shanghai.
- In March 2024, Merck invested over €300 million in a new Bioprocessing Production Center in Daejeon, South Korea, marking its Life Science business sector’s largest investment in the Asia-Pacific region so far. This significant investment underscores Merck’s dedication to expanding its capabilities in this rapidly growing area.
Philips-Respironics
Company Overview
| Establishment Year | 1976 |
| Headquarter | Murrysville, Pennsylvania, U.S. |
| Key Management | Don Spence (President and CEO) |
| Revenue (US$ Bn) | $ 1.05 Billion (2022) |
| Headcount | ~ 4,900 (2022) |
| Website | http://www.respironics.com/ |
Business Description
Philips Respironics, a subsidiary of Royal Philips, is a leading innovator in sleep and respiratory care, dedicated to improving patient outcomes for those with sleep disorders like obstructive and central sleep apnea.
Renowned for its CPAP and BiPAP machines, masks, and diagnostic tools, the company emphasizes technology-driven, user-friendly solutions to enhance treatment compliance and patient quality of life.
With its global operations headquartered in Pittsburgh, Pennsylvania, Philips Respironics has a strong international presence, showcasing its commitment to advancing sleep health worldwide.
Through ongoing research and development, it continues to introduce cutting-edge solutions, playing a pivotal role in the evolution of sleep medicine and respiratory care.
Geographical Presence
Philips Respironics, a division of Philips specializing in sleep and respiratory care solutions, has a strong global presence spanning North America, Europe, Asia Pacific, Latin America, and the Middle East.
In North America, it operates extensively in the United States and Canada, while in Europe, it serves key markets such as the UK, Germany, France, Italy, and the Netherlands.
The Asia Pacific region, including China, Japan, Australia, India, and South Korea, is also a significant focus due to rising healthcare awareness.
Additionally, Philips Respironics reaches Latin American countries like Brazil, Mexico, Argentina, and Chile, as well as the Middle East and Africa, including Saudi Arabia, UAE, South Africa, and Egypt.
This global reach highlights the company’s dedication to innovative solutions and enhancing respiratory health globally.
Recent Developments
- In March 2024, Philips Avent unveiled its new brand positioning, “Share the Care,” in North America, using the Daylight Saving Time Change to convey a strong message about supporting mothers.
- In March 2024, Philips announced a broader partnership with AWS to meet the increasing demand for secure, scalable, cloud-based digital pathology solutions.
Itamar-Medical
Company Overview
| Establishment Year | 1995 |
| Headquarter | Caesarea, Israel |
| Key Management | Giora Yaron (President) |
| Revenue (US$ Bn) | $ 33.9 Million (2019) |
| Headcount | ~ 184 (2019) |
| Website | https://www.itamar-medical.com/ |
Business Description
Itamar Medical Ltd., based in Caesarea, Israel, is at the forefront of sleep medicine, specializing in diagnostic tools for sleep disorders, notably sleep apnea.
The company is renowned for its innovative WatchPAT home sleep apnea test. It uses peripheral arterial tone signal technology for non-invasive, accurate diagnostics, facilitating easier access to sleep apnea diagnosis.
Itamar Medical’s focus on the intersection of cardiovascular health and sleep disorders fills a crucial gap in healthcare, offering solutions that cater to patients with sleep-related breathing disorders and cardiovascular risks.
Operating globally, Itamar Medical is committed to advancing sleep medicine through research, development, and collaboration, making significant contributions to the field and improving patient health outcomes worldwide.
Geographical Presence
Itamar Medical Ltd, based in Israel, boasts a strong global footprint across North America, Europe, and Asia-Pacific.
Utilizing Israel’s innovation hub, the company strategically expands its market, offering advanced solutions for sleep apnea and cardiovascular health worldwide.
In North America, Itamar targets key markets like the US and Canada through robust distribution networks. Similarly, in Europe, covering the UK, Germany, France, and Italy, the company navigates diverse healthcare landscapes via strategic partnerships.
In the dynamic Asia-Pacific region, including Japan, China, Australia, and South Korea, Itamar seizes opportunities by complying with local regulations and forming alliances to drive widespread adoption of its innovative technologies.
Overall, Itamar Medical’s global presence underscores its dedication to enhancing healthcare outcomes globally.
Recent Developments
- In January 2021, Itamar Medical acquired Spry Health to broaden its product range into remote monitoring and enhance support for patients.
DeVilbiss
Company Overview
| Establishment Year | 2015 |
| Headquarter | Somerset, Pennsylvania U.S. |
| Key Management | Derek Lampert (CEO) |
| Revenue (US$ Bn) | $ 1.0 Billion (2022) |
| Headcount | ~ 1,500 (2022) |
| Website | http://www.drivemedical.com/ |
Business Description
DeVilbiss Healthcare stands out in the sleep medicine landscape for its development, manufacture, and marketing of advanced respiratory and sleep therapy products, including CPAP and BiPAP machines, along with a range of therapy masks for obstructive sleep apnea and other sleep-related disorders.
Renowned for its commitment to innovation and patient care, DeVilbiss designs devices that are both effective and user-friendly, featuring humidification systems for comfort and data tracking for monitoring progress.
The company’s global presence and dedication to quality have cemented its reputation as a reliable provider in the sleep medicine market, continually advancing technology to enhance patient compliance and improve the quality of sleep for those with respiratory and sleep disorders.
Geographical Presence
DeVilbiss Healthcare has a strong global presence, with extensive distribution networks spanning North America, Europe, Asia, Latin America, and the Middle East.
In North America, it serves the United States and Canada through reliable partners. In Europe, including key markets like the UK, Germany, and France, the company ensures accessibility to its healthcare solutions.
It has also successfully entered emerging markets in Asia, Latin America, and the Middle East, forming strategic partnerships in countries such as China, India, Brazil, and the UAE.
This broad geographical reach highlights DeVilbiss Healthcare’s dedication to providing innovative healthcare solutions worldwide.
Recent Development
- In February 2022, DeVilbiss Healthcare expanded its respiratory product range by launching the Vacu-Aide® 7325 Suction Machine, an update to the Vacu-Aide® Suction Unit. This new version offers a more compact and quieter suction solution for users.
- In November 2021, DeVilbiss Healthcare teamed up with the BILT Video Assembly App to simplify product assembly, saving users both time and effort.
SomnoMed
Company Overview
| Establishment Year | 1987 |
| Headquarter | Sydney, Australia |
| Key Management | Neil Verdal-Austin (CEO) |
| Revenue (US$ Bn) | $ 15.6 Billion (2022) |
| Headcount | ~ 1,000 (2022) |
| Website | https://somnomed.com/en |
Business Description
SomnoMed Limited, a global leader in sleep medicine, specializes in creating and distributing oral appliances like the SomnoDent® for treating sleep-related disorders such as obstructive sleep apnea and snoring.
Recognized for offering an innovative alternative to CPAP therapy, SomnoMed’s products are designed for comfort and effectiveness, emphasizing a non-invasive approach to ensuring uninterrupted breathing during sleep.
With a strong commitment to research, development, and education, the company supports both healthcare professionals and patients in managing sleep disorders.
Headquartered in Australia, SomnoMed’s international operations extend across North America, Europe, and Asia, reflecting its dedication to providing accessible treatment solutions worldwide and improving the quality of life for those with sleep disorders.
Geographical Presence
SomnoMed Limited, a leading provider of oral appliance therapy for sleep-related breathing disorders, has a global presence across key regions.
The company has established strong partnerships with healthcare providers in North America (primarily the US and Canada) and Europe (including the UK, Germany, and France).
It has also expanded into the Asia-Pacific region, covering countries such as Australia, Japan, and China, to tackle the growing prevalence of sleep disorders.
With a focus on emerging markets in Latin America, the Middle East, and Africa, SomnoMed remains committed to enhancing patient outcomes and advancing dental sleep medicine worldwide.
Recent Development
- In June 2023, SomnoMed North America named Nexus Dental Systems (Nexus) as their chosen partner to provide sleep dentistry training and medical billing services across the Department of Defense (DOD), Veterans Affairs (VA), and commercial sectors.
- In November 2021, SomnoMed Canada Inc. acquired Strong Dental’s business in Leamington, Ontario, Canada.
Oventus
Company Overview
| Establishment Year | 2015 |
| Headquarter | Brisbane, Australia |
| Key Management | John Cox (CEO) |
| Revenue (US$ Bn) | $ 50.0 Million (2022) |
| Headcount | ~ 1,000 (2022) |
| Website | http://oventus.com.au/ |
About Oventus Medical
Oventus Medical Limited, based in Brisbane, Australia, is revolutionizing the sleep medicine field with its innovative treatments for obstructive sleep apnea (OSA) and snoring.
Utilizing its unique O2Vent® technology, Oventus offers oral appliances that direct airflow to bypass obstructions, presenting a viable alternative for those who find CPAP machines challenging.
Focused on comfort and efficacy, Oventus is expanding globally, continuously advancing its products through research and collaboration with specialists.
This commitment positions Oventus as a pioneering force in developing more accessible and effective sleep disorder solutions, enhancing patient health and sleep quality worldwide.
Geographical Presence
Oventus Medical Limited has established a strong global presence, focusing on key markets where sleep-disordered breathing conditions are prevalent.
With a significant presence in North America, particularly the United States and Canada, the company partners with healthcare providers to offer innovative solutions.
It has also expanded into Europe, targeting countries with increasing awareness of sleep apnea. In the Asia-Pacific region, including Australia and New Zealand, Oventus taps into emerging markets to meet the rising demand for effective sleep apnea management.
Overall, Oventus Medical Limited’s strategic expansion ensures broad access to its advanced products, contributing significantly to combating sleep-related breathing disorders worldwide.
Recent Developments
- In January 2024, Open Airway Dental Solutions Ltd (OADS), a Canadian med-tech company specializing in the distribution of sleep dentistry products, acquired Australia’s oral appliance manufacturer, Oventus Medical Ltd.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
